Last reviewed · How we verify
Treatment simplification
Treatment simplification refers to reducing the complexity of antiretroviral regimens by consolidating multiple drugs into fewer, more convenient formulations.
Treatment simplification refers to reducing the complexity of antiretroviral regimens by consolidating multiple drugs into fewer, more convenient formulations. Used for HIV-1 infection (treatment simplification strategy).
At a glance
| Generic name | Treatment simplification |
|---|---|
| Also known as | Darunavir 800mg plus Stribild tablet once daily |
| Sponsor | University of British Columbia |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This approach aims to improve medication adherence and quality of life in HIV patients by decreasing pill burden and dosing frequency. Simplified regimens typically combine multiple antiretroviral agents into single-tablet or dual-tablet formulations, maintaining therapeutic efficacy while enhancing patient convenience and compliance.
Approved indications
- HIV-1 infection (treatment simplification strategy)
Common side effects
Key clinical trials
- Medication Withdrawal in Stable HF With Improved LVEF (PHASE2, PHASE3)
- Which Exercise for Low Back Pain? Predicting Response to Exercise for Patients With Low Back Pain (NA)
- Therapeutic Adherence in Uncontrolled Arterial Hypertension (NA)
- Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen (PHASE3)
- How Simplified Language Affects Comprehension and Learning in Young Autistic Children (NA)
- Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs (PHASE3)
- Effects of ART Simplification on Inflammatory Markers in CoRis (AIR)
- Virtual Reality, Debriefing and Chronic Pain (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment simplification CI brief — competitive landscape report
- Treatment simplification updates RSS · CI watch RSS
- University of British Columbia portfolio CI